세계 전이성간암 치료제 시장 : 규모, 점유율, 동향 분석 보고서 - 치료 유형별, 원발성 암별, 유통 채널별, 지역별, 부문 예측(2024-2030년)

Liver Metastases Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Immunotherapy), By Primary Cancer, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,302,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,698,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,488,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

간 전이 치료 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계 간 전이 치료 시장은 2030년까지 26억 6,000만 달러에 이를 것으로 예측되며, 2024년부터 2030년까지 복합 연간 성장률(CAGR) 7.3%로 확대될 전망입니다.

대상 질환의 유병률 상승, 개발도상국에서 암의 진행기 진단, 제품 승인 수 증가가 업계의 성장을 가속할 것으로 예상됩니다.

결장암, 유방암, 폐암은 간으로 전이하는 주요 유형 중 일부입니다. 대장암의 이환율은 2020년 188만명에서 2030년 245만명으로 증가할 것으로 예상됩니다. 한편 유방암의 이환율은 2020년 226만명에서 2030년 274만명으로 증가할 것으로 예상됩니다. 이러한 주요 적응증의 이환율 증가는 시장 성장을 가속할 것으로 예상됩니다.

중저소득 국가의 암 환자의 대부분은 치료 옵션의 가용성이 낮은 진행 단계에서 진단됩니다. 조기 진단 방법을 사용할 수 없으며 진단 약물에 대한 불투명한 상환 시나리오가 진단 지연의 주된 이유입니다. 진단의 진행기/전이기는 이 분야에 유리한 성장 기회를 가져옵니다.

한편, 특히 개발도상국이나 LMICS에서는 암이 진행된 단계에서 진단되어도 제품이나 적절한 상환을 얻을 수 없기 때문에 그러한 진행 단계에서의 치료율은 현저하게 낮습니다. 이러한 요인이 시장 성장을 억제할 것으로 예상됩니다.

전이성간암 치료제 시장 보고서 하이라이트

• 치료 유형별로는 기존의 화학요법보다 높은 가격으로 승인된 약이 존재하는 표적 치료 분야가 56.52%의 점유율로 시장을 독점했습니다.
• 2023년에는 대장암이 40.55%의 점유율로 전이성간암 치료제 시장을 독점했습니다. 대장암의 약 25-30%가 간으로 전이합니다. CCLM에 대한 다양한 치료 옵션을 사용할 수 있다는 것은이 부문의 이점을 더욱 향상시킵니다.
• 유통 채널별로는 2023년에 60.07%의 점유율을 가진 병원 약국 부문이 시장을 독점했습니다. 간 전이 치료에 대한 높은 입원률은이 부문 우위의 주요 요인 중 하나입니다.
• 지역별로는 북미가 2023년 세계 간 전이 치료 시장에서 높은 수익 점유율을 차지하고 있습니다. 그러나 아시아태평양은 예측기간 동안 가장 급성장하는 지역이 될 전망입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 전이성간암 치료제 시장 변수, 동향 및 범위

• 시장 계통 전망
  • 상위 시장 전망
• 치료 유형의 보급과 성장의 전망 매핑(2023년)
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 시장 분석 도구
  • 업계 분석 : Porter's Five Forces 분석
  • 업계 분석 :PESTEL

제4장 전이성간암 치료제 시장 : 치료 유형별 부문 분석(2018년-2030년)(백만 달러)

• 전이성간암 치료제 시장 : 치료 유형의 변동 분석

제5장 전이성간암 치료제 시장 : 원발암별 부문 분석(2018년-2030년)(백만 달러)

• 전이성간암 치료제 시장 : 원전 암의 변동 분석

제6장 전이성간암 치료제 시장 : 판매 채널별 부문 분석(2018년-2030년)(백만 달러)

• 전이성간암 치료제 시장 : 유통 채널의 변동 분석

제7장 전이성간암 치료제 시장 : 유형별, 제품별, 용도별 지역 추정,동향 분석

• 북미
• 유럽
• 아시아태평양
• 라틴아메리카
• 중동 및 아프리카(MEA)

제8장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
  • New product launch
  • Merger and acquisition
  • Licensing agreements
  • Conferences and campaigns
• 기업의 분류
  • 이노베이터
  • 시장의 리더
• 벤더 상황
  • List of key distributors and channel partners
  • Key customers
• 공개회사
  • 주요 기업의 시장 점유율 분석(2023년)
  • 기업의 시장 포지셔닝 분석
  • 히트맵 분석
  • 경쟁 대시보드 분석
• 비공개회사
  • 주요 신흥 기업 목록
  • 지역 네트워크 맵
• 기업 프로파일
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca
  • Bayer AG
  • Eli Lilly and Company
  • Ono Pharmaceutical
  • Pfizer, Inc.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Ltd.

BJH

영문 목차

영문목차

Liver Metastases Treatment Market Growth & Trends:

The global liver metastases treatment market is expected to reach USD 2.66 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 7.3% from 2024 to 2030. Rising prevalence of target disease, advanced stage diagnosis for cancer in developing countries, and increasing number of products approvals is expected to drive the industry growth.

Colorectal cancer, breast cancer, and lung cancer are some of the key types that metastasize to the liver. The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030. Whereas the incidence of breast cancer is expected to increase from 2.26 million in 2020 to 2.74 million in 2030. The rising incidence of these primary indications is expected to drive space growth.

Majority of the cancer cases in low and middle-income countries are diagnosed at advanced stages where the availability of therapeutic options is low. The lack of availability of early diagnostics methods combined with uncertain reimbursement scenario for diagnostics are major reasons for delayed diagnosis. The advanced/metastatic stage of diagnosis provide lucrative growth opportunities in this space.

On the other hand, if cancers are diagnosed at advanced stages particularly in developing nations and LMICS, the treatment rate at such advanced stages is significantly less, due to unavailability of products and proper reimbursement. This factor is expected to restrain space growth.

Liver Metastases Treatment Market Report Highlights:

• By treatment type, the targeted therapy segment dominated the market with a share of 56.52% to the presence of approved drugs with a price higher than traditional chemotherapy.
• In 2023, colorectal cancer dominated the liver metastases treatment market with a share of 40.55%. Around 25-30% of all colorectal cancers metastasize to the liver. The availability of various treatment options for CCLM further contributed to the segments' dominance.
• Based on distribution channel, the market was dominated by the hospital pharmacies segment with a share of 60.07% in 2023. The high rate of hospitalization for the treatment of liver metastases is one of the major factors for the dominance of this segment.
• By region, North America has a high revenue share in the global liver metastases treatment market in 2023. However, Asia Pacific is expected to be the fastest growing region during the forecast period.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation and Scope
  • 1.1.1 Regional scope
  • 1.1.2 Estimates and forecast timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis (Model 1)
    • 1.6.1.1 Approach 1: Commodity flow approach
• 1.7 Research Assumptions
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations
• 1.10 Objectives
  • 1.10.1 Objective 1
  • 1.10.2 Objective 2
  • 1.10.3 Objective 3
  • 1.10.4 Objective 4

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot
• 2.3 Competitive Landscape Snapshot

Chapter 3 Liver Metastases treatment Market Variables, Trends, and Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent market outlook
    • 3.1.1.1 Liver cancer treatment market
• 3.2 Penetration and Growth Prospect Mapping for Treatment Type, 2023
• 3.3 Market Dynamics
  • 3.3.1 Market driver analysis
    • 3.3.1.1 Approval of targeted therapy for the treatment of liver metastases
  • 3.3.2 Market restraint analysis
    • 3.3.2.1 Technological advancements for early diagnosis of cancer
• 3.4 Market Analysis Tools
  • 3.4.1 Industry analysis: porter's
    • 3.4.1.1 Threat of new entrants
    • 3.4.1.2 Bargaining power of buyers
    • 3.4.1.3 Competitive rivalry
    • 3.4.1.4 Threat of substitutes
    • 3.4.1.5 Bargaining power of suppliers
  • 3.4.2 Industry analysis: PESTEL
    • 3.4.2.1 Political & Legal
    • 3.4.2.2 Economical
    • 3.4.2.3 Technological

Chapter 4 Liver Metastases treatment Market: Segment Analysis, by Treatment Type, 2018 - 2030 (USD Million)

• 4.1 Liver Metastases treatment Market: Treatment Type Movement Analysis
  • 4.1.1 Chemotherapy
    • 4.1.1.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.1.2 Targeted Therapy
    • 4.1.2.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.1.3 Immunotherapy
    • 4.1.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Liver Metastases Treatment Market: Segment Analysis, by Primary Cancer, 2018 - 2030 (USD Million)

• 5.1 Liver Metastases treatment Market: Primary Cancer Movement Analysis
  • 5.1.1 Colorectal cancer
    • 5.1.1.1 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD million)
  • 5.1.2 Breast Cancer
    • 5.1.2.1 Breast cancer market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Liver Metastases treatment Market: Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)

• 6.1 Liver Metastases treatment Market: Distribution Channel Movement Analysis
  • 6.1.1 Hospital Pharmacies
    • 6.1.1.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.1.2 Specialty pharmacies
    • 6.1.2.1 Specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Liver Metastases treatment Market: Regional Estimates and Trend Analysis, by Type, Product, & Application

• 7.1 North America
  • 7.1.1 SWOT analysis
    • 7.1.1.1 North america liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.1.2 U.S.
    • 7.1.2.1 Key country dynamics
    • 7.1.2.2 Target disease prevalence
    • 7.1.2.3 Competitive scenario
    • 7.1.2.4 Regulatory framework
    • 7.1.2.5 Reimbursement scenario
    • 7.1.2.6 U.S. Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.1.3 Canada
    • 7.1.3.1 Key country dynamics
    • 7.1.3.2 Target disease prevalence
    • 7.1.3.3 Competitive scenario
    • 7.1.3.4 Regulatory framework
    • 7.1.3.5 Reimbursement scenario
    • 7.1.3.6 Canada liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.2 Europe
  • 7.2.1 SWOT analysis:
    • 7.2.1.1 Europe liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.2 Germany
    • 7.2.2.1 Key country dynamics
    • 7.2.2.2 Target disease prevalence
    • 7.2.2.3 Competitive scenario
    • 7.2.2.4 Regulatory framework
    • 7.2.2.5 Reimbursement scenario
    • 7.2.2.6 Germany Liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.3 UK
    • 7.2.3.1 Key country dynamics
    • 7.2.3.2 Target disease prevalence
    • 7.2.3.3 Competitive scenario
    • 7.2.3.4 Regulatory Framework
    • 7.2.3.5 Reimbursement Scenario
    • 7.2.3.6 UK liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.4 France
    • 7.2.4.1 Key country dynamics
    • 7.2.4.2 Target disease prevalence
    • 7.2.4.3 Competitive scenario
    • 7.2.4.4 Regulatory framework
    • 7.2.4.5 Reimbursement scenario
    • 7.2.4.6 France liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.5 Italy
    • 7.2.5.1 Key country dynamics
    • 7.2.5.2 Target disease prevalence
    • 7.2.5.3 Competitive scenario
    • 7.2.5.4 Regulatory framework
    • 7.2.5.5 Reimbursement scenario
    • 7.2.5.6 Italy liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.6 Spain
    • 7.2.6.1 Key country dynamics
    • 7.2.6.2 Target disease prevalence
    • 7.2.6.3 Competitive scenario
    • 7.2.6.4 Regulatory framework
    • 7.2.6.5 Reimbursement scenario
    • 7.2.6.6 Spain liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.7 Denmark
    • 7.2.7.1 Key country dynamics
    • 7.2.7.2 Target disease prevalence
    • 7.2.7.3 Competitive scenario
    • 7.2.7.4 Regulatory framework
    • 7.2.7.5 Reimbursement scenario
    • 7.2.7.6 Denmark liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.8 Sweden
    • 7.2.8.1 Key country dynamics
    • 7.2.8.2 Target disease prevalence
    • 7.2.8.3 Competitive scenario
    • 7.2.8.4 Regulatory framework
    • 7.2.8.5 Reimbursement scenario
    • 7.2.8.6 Sweden liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.2.9 Norway
    • 7.2.9.1 Key country dynamics
    • 7.2.9.2 Target disease prevalence
    • 7.2.9.3 Competitive scenario
    • 7.2.9.4 Regulatory framework
    • 7.2.9.5 Reimbursement scenario
    • 7.2.9.6 Norway liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.3 Asia Pacific
  • 7.3.1 SWOT analysis:
    • 7.3.1.1 Asia Pacific liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.2 Japan
    • 7.3.2.1 Key country dynamics
    • 7.3.2.2 Target disease prevalence
    • 7.3.2.3 Competitive scenario
    • 7.3.2.4 Regulatory framework
    • 7.3.2.5 Reimbursement scenario
    • 7.3.2.6 Japan liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.3 China
    • 7.3.3.1 Key country dynamics
    • 7.3.3.2 Target disease prevalence
    • 7.3.3.3 Competitive scenario
    • 7.3.3.4 Regulatory framework
    • 7.3.3.5 Reimbursement scenario
    • 7.3.3.6 China liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.4 India
    • 7.3.4.1 Key country dynamics
    • 7.3.4.2 Target disease prevalence
    • 7.3.4.3 Competitive scenario
    • 7.3.4.4 Regulatory framework
    • 7.3.4.5 Reimbursement scenario
    • 7.3.4.6 India liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.5 Australia
    • 7.3.5.1 Key country dynamics
    • 7.3.5.2 Target disease prevalence
    • 7.3.5.3 Competitive scenario
    • 7.3.5.4 Regulatory framework & reimbursement scenario
    • 7.3.5.5 Australia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.6 Thailand
    • 7.3.6.1 Key country dynamics
    • 7.3.6.2 Target disease prevalence
    • 7.3.6.3 Competitive scenario
    • 7.3.6.4 Regulatory framework & reimbursement scenario
    • 7.3.6.5 Thailand liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.3.7 South Korea
    • 7.3.7.1 Key country dynamics
    • 7.3.7.2 Target disease prevalence
    • 7.3.7.3 Competitive scenario
    • 7.3.7.4 Regulatory framework & reimbursement scenario
    • 7.3.7.5 South Korea liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.4 Latin America
  • 7.4.1 SWOT analysis:
    • 7.4.1.1 Latin America liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4.2 Brazil
    • 7.4.2.1 Key country dynamics
    • 7.4.2.2 Target disease prevalence
    • 7.4.2.3 Competitive scenario
    • 7.4.2.4 Regulatory framework
    • 7.4.2.5 Reimbursement scenario
    • 7.4.2.6 Brazil liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4.3 Mexico
    • 7.4.3.1 Key country dynamics
    • 7.4.3.2 Target disease prevalence
    • 7.4.3.3 Competitive scenario
    • 7.4.3.4 Regulatory framework
    • 7.4.3.5 Reimbursement scenario
    • 7.4.3.6 Mexico liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.4.4 Argentina
    • 7.4.4.1 Key country dynamics
    • 7.4.4.2 Target disease prevalence
    • 7.4.4.3 Competitive scenario
    • 7.4.4.4 Regulatory framework
    • 7.4.4.5 Reimbursement scenario
    • 7.4.4.6 Argentina liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
• 7.5 Middle East & Africa (MEA)
  • 7.5.1 SWOT analysis:
    • 7.5.1.1 Middle East & Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.2 South Africa
    • 7.5.2.1 Key Country dynamics
    • 7.5.2.2 Target disease prevalence
    • 7.5.2.3 Competitive scenario
    • 7.5.2.4 Regulatory framework
    • 7.5.2.5 Reimbursement scenario
    • 7.5.2.6 South Africa liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.3 Saudi Arabia
    • 7.5.3.1 Key country dynamics
    • 7.5.3.2 Target disease prevalence
    • 7.5.3.3 Competitive scenario
    • 7.5.3.4 Regulatory framework
    • 7.5.3.5 Reimbursement scenario
    • 7.5.3.6 Saudi Arabia liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.4 UAE
    • 7.5.4.1 Key country dynamics
    • 7.5.4.2 Target disease prevalence
    • 7.5.4.3 Competitive scenario
    • 7.5.4.4 Regulatory framework
    • 7.5.4.5 Reimbursement scenario
    • 7.5.4.6 UAE liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
  • 7.5.5 Kuwait
    • 7.5.5.1 Key country dynamics
    • 7.5.5.2 Target disease prevalence
    • 7.5.5.3 Competitive scenario
    • 7.5.5.4 Regulatory framework
    • 7.5.5.5 Reimbursement Scenario
    • 7.5.5.6 Kuwait liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)
    • 7.5.5.7 Rest of MEA liver metastases treatment market estimates and forecasts, 2018 - 2030 (USD million)

Chapter 8 Competitive Landscape

• 8.1 Recent Developments & Impact Analysis, by Key Market Participants
  • 8.1.1 New product launch
  • 8.1.2 Merger and acquisition
  • 8.1.3 Licensing agreements
  • 8.1.4 Conferences and campaigns
• 8.2 Company Categorization
  • 8.2.1 Innovators
  • 8.2.2 Market leaders
• 8.3 Vendor Landscape
  • 8.3.1 List of key distributors and channel partners
  • 8.3.2 Key customers
• 8.4 Public Companies
  • 8.4.1 Key company market share analysis, 2023
  • 8.4.2 Company market position analysis
  • 8.4.3 Heat map analysis
  • 8.4.4 Competitive dashboard analysis
    • 8.4.4.1 Market differentiators
• 8.5 Private Companies
  • 8.5.1 List of key emerging companies
  • 8.5.2 Regional network map
• 8.6 Company Profiles
  • 8.6.1. F. Hoffmann-La Roche Ltd.
    • 8.6.1.1 Company overview
    • 8.6.1.2 Financial performance
    • 8.6.1.3 Product benchmarking
    • 8.6.1.4 Strategic initiatives
  • 8.6.2 AstraZeneca
    • 8.6.2.1 Company overview
    • 8.6.2.2 Financial performance
    • 8.6.2.3 Product benchmarking
    • 8.6.2.4 Strategic initiatives
  • 8.6.3 Bayer AG
    • 8.6.3.1 Company overview
    • 8.6.3.2 Financial performance
    • 8.6.3.3 Product benchmarking
    • 8.6.3.4 Strategic initiatives
  • 8.6.4 Eli Lilly and Company
    • 8.6.4.1 Company overview
    • 8.6.4.2 Financial performance
    • 8.6.4.3 Product benchmarking
    • 8.6.4.4 Strategic initiatives
  • 8.6.5 Ono Pharmaceutical
    • 8.6.5.1 Company overview
    • 8.6.5.2 Financial performance
    • 8.6.5.3 Product benchmarking
    • 8.6.5.4 Strategic initiatives
  • 8.6.6 Pfizer, Inc.
    • 8.6.6.1 Company overview
    • 8.6.6.2 Financial performance
    • 8.6.6.3 Product benchmarking
    • 8.6.6.4 Strategic initiatives
  • 8.6.7 Bristol-Myers Squibb Company
    • 8.6.7.1 Company overview
    • 8.6.7.2 Financial performance
    • 8.6.7.3 Product benchmarking
    • 8.6.7.4 Strategic initiatives
  • 8.6.8 Cadila Pharmaceuticals Ltd.
    • 8.6.8.1 Company overview
    • 8.6.8.2 Financial performance
    • 8.6.8.3 Product benchmarking
    • 8.6.8.4 Strategic initiatives

관련자료